Key Points
- Director Richard Buller sold 3,900 Celcuity shares at an average price of $96.73 for $377,247, reducing his stake by 34.95% to 7,260 shares; the sale was disclosed on an SEC Form 4.
- CELC traded up to $97.50 on heavy volume (1.29M) and has a market cap of $4.51B, a 50-day/200-day moving average of $65.17/$39.65, and a one‑year range of $7.57–$101.03 with a negative P/E.
- Analyst sentiment is mixed — MarketBeat shows a consensus "Moderate Buy" with a $97 target while firms range from sell (Weiss) to outperform/buy (Wolfe, Craig Hallum) — and the company reported Q earnings of ($0.92) EPS, beating estimates of ($1.05).
Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director Richard Buller sold 3,900 shares of Celcuity stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the sale, the director owned 7,260 shares in the company, valued at approximately $702,259.80. This represents a 34.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Celcuity Price Performance
CELC traded up $3.50 on Friday, reaching $97.50. The company had a trading volume of 1,292,029 shares, compared to its average volume of 916,267. The company has a fifty day moving average of $65.17 and a 200-day moving average of $39.65. The company has a market capitalization of $4.51 billion, a P/E ratio of -26.57 and a beta of 0.72. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. Celcuity, Inc. has a one year low of $7.57 and a one year high of $101.03.
Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.13. As a group, equities research analysts anticipate that Celcuity, Inc. will post -2.62 earnings per share for the current year.
Institutional Trading of Celcuity
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Ogorek Anthony Joseph NY ADV purchased a new stake in Celcuity during the third quarter valued at about $27,000. US Bancorp DE raised its holdings in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after acquiring an additional 143 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Celcuity by 211.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock worth $74,000 after purchasing an additional 3,766 shares during the period. Finally, Avanza Fonder AB purchased a new position in Celcuity during the 3rd quarter worth approximately $79,000. Institutional investors and hedge funds own 63.33% of the company's stock.
Wall Street Analyst Weigh In
CELC has been the subject of a number of research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Celcuity in a research report on Wednesday, October 8th. Wall Street Zen downgraded Celcuity from a "hold" rating to a "sell" rating in a research note on Sunday, October 26th. Wolfe Research started coverage on Celcuity in a research note on Tuesday. They set an "outperform" rating and a $110.00 target price for the company. Craig Hallum lifted their target price on Celcuity from $96.00 to $108.00 and gave the stock a "buy" rating in a report on Thursday, November 13th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $94.00 price target (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $97.00.
Check Out Our Latest Stock Report on Celcuity
Celcuity Company Profile
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
